摘要
目的探讨低分子肝素钙联合奥扎格雷钠治疗肺心病急性发作的临床效果。方法将2008年1月～2009年1月间在我院住院治疗的肺心病急性发作患者102例随机分为A组、B组和C组,A组给予低分子肝素钙,B组给予奥扎格雷钠,C组联合应用低分子肝素钙和奥扎格雷钠,评估三组治疗效果。结果治疗后三组患者PO2、PCO2均较治疗前好转,三组分别比较差异具有统计学意义(P<0.05)。A组、B组PO2明显低于C组,两组分别比较差异具有统计学意义(P<0.05);A组PO2与B组比较差异无统计学意义(P>0.05)。A组、B组PCO2明显高于C组,两组分别比较差异具有统计学意义(P<0.05);A组PCO2与B组比较差异无统计学意义(P>0.05)。A组总有效率为76.47%,B组为73.53%,C组为97.06%;A组、B组总有效率明显低于C组,两组分别比较差异具有统计学意义(P<0.05);A组总有效率与B组比较差异无统计学意义(P>0.05)。结论低分子肝素钙联合奥扎格雷钠治疗肺心病急性发作疗效优于两者单纯用药,值得推荐应用。
Objective To investigate the effect of low molecular heparin calcium combined with sodium ozagrel in the treatment for acute attack of pulmonary heart disease. Methods 102 cases with acute attack of pulmonary heart disease in our hospital from January 2008 to January 2009 were randomly divided into the A group, B group and C group, A group received the treatment of low molecular heparin calcium, B group received the treatment of sodium ozagrel, and C group received the treatment of low molecular heparin calcium combined with sodium ozagrel. Results PO2 and PCO2 of three group after treatment was superior to that before treatment, and there was significant difference among them respectively （P〈0.05）. PO2 in the A group and B group was lower than that in C group, and there was significant difference in them respectively （P〈0.05）. There was no significant difference with PO2 in A group and B group （P〉0.05）. PCO2 in the A group and in B group was higher than that in C group, and there was significant difference in them respectively （P〈0.05）. There was no significant difference with PCO2 in A group and B group （P〉0.05）. The total effective rate was 76.47% in A group, 73.53% ha B group and 97.06% in C group, and the total effective rate in A group and in B group was lower than that in C group, and there was significant difference in them re- spectively （P〈0.05）. There was no significant difference in A group and B group （P〉0.05）. Conclusion The effect of low molecular heparin calcium combined with sodium ozagrel in the treatment for acute attack of pulmonary heart disease is obvious, which is worthy of clinical application.
出处
《临床医学工程》
2010年第4期93-94,共2页
Clinical Medicine & Engineering
关键词
低分子肝素钙
奥扎格雷钠
肺心病
Low molecular heparin calcium
Sodium ozagrel
Pulmonary heart disease
